Fox Run Management L.L.C. Invests $2.12 Million in Zoetis Inc. $ZTS

Fox Run Management L.L.C. acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 29,511 shares of the company’s stock, valued at approximately $2,121,000. Zoetis comprises approximately 0.4% of Fox Run Management L.L.C.’s portfolio, making the stock its 19th largest position.

A number of other large investors have also made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in Zoetis in the 2nd quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $28,000. Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $73.64 on Friday. The business has a 50-day moving average of $76.30 and a two-hundred day moving average of $99.01. The firm has a market capitalization of $30.43 billion, a PE ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 12 month low of $71.45 and a 12 month high of $160.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company posted $1.76 EPS. The company’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 34.93%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Zacks Research lowered Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.